Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma
ABSTRACT Purpose Upper tract urothelial carcinoma (UTUC) presents a higher incidence rate in Taiwan compared to Western societies. The aim of this study is to investigate the potential of metformin in improving survival outcomes for patients with UTUC in Taiwan. Material and Methods This retrospecti...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70567 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543388039479296 |
|---|---|
| author | Hsiang Ying Lee Po‐Hung Lin See‐Tong Pang Jen‐Kai Fang Chung‐You Tsai Yao‐Chou Tsai Yung‐Tai Chen Wei‐Chieh Chen Hsin‐Chih Yeh Wei‐Ming Li |
| author_facet | Hsiang Ying Lee Po‐Hung Lin See‐Tong Pang Jen‐Kai Fang Chung‐You Tsai Yao‐Chou Tsai Yung‐Tai Chen Wei‐Chieh Chen Hsin‐Chih Yeh Wei‐Ming Li |
| author_sort | Hsiang Ying Lee |
| collection | DOAJ |
| description | ABSTRACT Purpose Upper tract urothelial carcinoma (UTUC) presents a higher incidence rate in Taiwan compared to Western societies. The aim of this study is to investigate the potential of metformin in improving survival outcomes for patients with UTUC in Taiwan. Material and Methods This retrospective study included 940 patients with UTUC and type 2 diabetes from the Taiwan UTUC Collaboration Group, spanning 21 hospitals from July 1988 to September 2023. Patients were divided into two groups: those treated with metformin (n = 215) and those without metformin treatment (n = 725). Parameters analyzed included age, BMI, renal function, tumor grade and location, and pathological staging. Oncological outcomes measured were overall survival (OS), cancer‐specific survival (CSS), and bladder recurrence‐free survival (BRFS). Statistical analysis involved the use of Student's t‐test, Mann–Whitney test, Chi‐squared test, Fisher's exact test, and Cox proportional hazard regression. Results Significant differences were observed between the two groups in BMI, preoperative creatinine, eGFR, tumor location, tumor laterality, tumor size, and pathological grade and T stage. Patients treated with metformin exhibited a lower risk of CSS (HR = 0.619; p = 0.018) and improved OS (HR = 0.713; p = 0.024), although no significant association was found with BRFS (HR = 1.034; p = 0.791). The protective effect of metformin on OS was particularly significant in patients with advanced T stage, metastasis, and high‐grade tumors. Conclusion The study suggests that metformin use in UTUC patients with diabetes is associated with improved OS and CSS but not BRFS. The underlying mechanisms warrant further investigation. Repurposing metformin, a well‐established and safe drug, may develop new therapeutic strategies for UTUC. |
| format | Article |
| id | doaj-art-0cf21f82329e40ec9989ae087ec7e46d |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-0cf21f82329e40ec9989ae087ec7e46d2025-01-13T13:22:39ZengWileyCancer Medicine2045-76342025-01-01141n/an/a10.1002/cam4.70567Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial CarcinomaHsiang Ying Lee0Po‐Hung Lin1See‐Tong Pang2Jen‐Kai Fang3Chung‐You Tsai4Yao‐Chou Tsai5Yung‐Tai Chen6Wei‐Chieh Chen7Hsin‐Chih Yeh8Wei‐Ming Li9Department of Urology, Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDivision of Urology, Department of Surgery Chang Gung Memorial Hospital, Linkou Branch Taoyuan TaiwanDivision of Urology China Medical University Hospital Taichung TaiwanDepartment of Urology Far Eastern Memorial Hospital TaiwanDivision of Urology, Taipei Tzu Chi Hospital Taiwan Urological Association Collaborative Research Organization Taipei TaiwanDepartment of Urology Taiwan Adventist Hospital Taipei TaiwanDepartment of Urology Taipei Medical University Taipei TaiwanDepartment of Urology, Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung TaiwanDepartment of Urology, Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung TaiwanABSTRACT Purpose Upper tract urothelial carcinoma (UTUC) presents a higher incidence rate in Taiwan compared to Western societies. The aim of this study is to investigate the potential of metformin in improving survival outcomes for patients with UTUC in Taiwan. Material and Methods This retrospective study included 940 patients with UTUC and type 2 diabetes from the Taiwan UTUC Collaboration Group, spanning 21 hospitals from July 1988 to September 2023. Patients were divided into two groups: those treated with metformin (n = 215) and those without metformin treatment (n = 725). Parameters analyzed included age, BMI, renal function, tumor grade and location, and pathological staging. Oncological outcomes measured were overall survival (OS), cancer‐specific survival (CSS), and bladder recurrence‐free survival (BRFS). Statistical analysis involved the use of Student's t‐test, Mann–Whitney test, Chi‐squared test, Fisher's exact test, and Cox proportional hazard regression. Results Significant differences were observed between the two groups in BMI, preoperative creatinine, eGFR, tumor location, tumor laterality, tumor size, and pathological grade and T stage. Patients treated with metformin exhibited a lower risk of CSS (HR = 0.619; p = 0.018) and improved OS (HR = 0.713; p = 0.024), although no significant association was found with BRFS (HR = 1.034; p = 0.791). The protective effect of metformin on OS was particularly significant in patients with advanced T stage, metastasis, and high‐grade tumors. Conclusion The study suggests that metformin use in UTUC patients with diabetes is associated with improved OS and CSS but not BRFS. The underlying mechanisms warrant further investigation. Repurposing metformin, a well‐established and safe drug, may develop new therapeutic strategies for UTUC.https://doi.org/10.1002/cam4.70567metforminSurvival outcomeupper tract urothelial carcinoma |
| spellingShingle | Hsiang Ying Lee Po‐Hung Lin See‐Tong Pang Jen‐Kai Fang Chung‐You Tsai Yao‐Chou Tsai Yung‐Tai Chen Wei‐Chieh Chen Hsin‐Chih Yeh Wei‐Ming Li Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma Cancer Medicine metformin Survival outcome upper tract urothelial carcinoma |
| title | Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma |
| title_full | Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma |
| title_fullStr | Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma |
| title_full_unstemmed | Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma |
| title_short | Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma |
| title_sort | repurposing of metformin to improve survival outcomes in patients with upper tract urothelial carcinoma |
| topic | metformin Survival outcome upper tract urothelial carcinoma |
| url | https://doi.org/10.1002/cam4.70567 |
| work_keys_str_mv | AT hsiangyinglee repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT pohunglin repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT seetongpang repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT jenkaifang repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT chungyoutsai repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT yaochoutsai repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT yungtaichen repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT weichiehchen repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT hsinchihyeh repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma AT weimingli repurposingofmetformintoimprovesurvivaloutcomesinpatientswithuppertracturothelialcarcinoma |